Cancer Nanomedicine Gets a Boost: Onco-Innovations' ONC010 Advances

For decades, chemotherapy has carried a basic trade-off. The same drugs that kill cancer cells can also damage healthy tissue, leading to toxicity that can limit dosing, interrupt treatment, and reduce quality of life. Nanomedicine emerged as a strategy to change how a drug distributes throughout the body. By packaging the drug in nanoscale carriers, these formulations keep more drug in circulation long enough to accumulate in tumors, while reducing unnecessary exposure in healthy tissue. Early enthusiasm gave way to skepticism as many experimental formulations failed to translate from animal models into clinical products. Now the field appears to be turning a corner, with more than 20 approved formulations improving therapeutic index and patient quality of life during treatment.

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is a Canadian oncology company developing inhibitors of Polynucleotide Kinase Phosphatase, or PNKP, an enzyme central to repairing DNA strand breaks. Their lead drug candidate, ONC010, pairs a small-molecule PNKP inhibitor with a polymer nanodelivery system designed to extend circulation, increase drug retention in tumor, and improve tolerability. Recent manufacturing updates, including kilogram-scale precursor production and a proposed Nanosoft Polymers collaboration, point to a sharpening focus on scalability, reproducibility, and regulatory readiness ahead of first-in-human studies.

The news release was disseminated on behalf of Onco-Innovations Ltd. and may include paid advertising. For more information, readers can explore the company’s newsroom at https://nnw.fm/ONNVF. NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.